Findings that correlate Epstein-Barr virus (EBV) status and solid tumors could mean that future cancer treatment may be guided by a patient's EBV status.
Researchers are heartened by evidence that demethylating agents may strip tumors of their epigenetic resistance, opening up the door for treatment with immunotherapies.
Endocrine Cancer News
Sharing health information about an older patient with family may have unintended consequences.
Sign Up for Free e-newsletters
Breast Cancer Awareness Month Poll
Cancer Therapy Advisor Articles
- Will Epigenetic Drugs Improve Immunotherapy Outcomes?
- Preoperative Breast MRI Associated With Longer Wait Time to Surgery
- Quitting Smoking Prior to Chemo Linked to Improved Survival Rate in Stage 4 Lung Cancer
- PD-L1 May Predict Response to TKIs, VEGFs in Metastatic Clear Cell Renal Cell Carcinoma
- Hyper-CVAD Plus Ponatinib May Be Effective for Newly Diagnosed Ph+ Acute Leukemia
- Olaparib Plus Paclitaxel Active in Metastatic Gastric Cancer
- For Metastatic Gastric Cancer, Modified DCF Should Be First-Line Option
- Routine CT Scans for B-cell Lymphoma Patients in Complete Remission Not Recommended
- Viral MicroRNA Expression Linked to Worse Clinical Outcomes in Early Stage Malignancies
- Prognostic Markers for Survival in Mycosis Fundoides, Sézary Syndrome Identified
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|